Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05405387RecruitingPhase 2
Budesonide to prevent serious diarrhea after stem cell transplant
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
Salt Lake City, UtahAges 18 years+ - NCT05401175Recruiting
Self-transfusion to protect bone marrow during cervical cancer treatment
This trial studies whether returning your own blood stem cells back to you (from a processed blood sample) can help protect your bone marrow while you receive chemotherapy and/or radiation for cervical cancer. It may help reduce treatment-related damage to the bone marrow that produces blood cells.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT05351788RecruitingPhase 2
Study drug combo for advanced lung cancer with specific gene results
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Guangzhou, GuangdongAges 18–75 - NCT05316129RecruitingPhase 1
Trial of your own engineered T cells for ovarian cancer
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
Tampa, FloridaAges 18 years+ - NCT05328024Recruiting
Testing who benefits from anti–PD-1 immunotherapy in head cancer
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Strasbourg, FranceAges 18 years+ - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+ - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05289687RecruitingPhase 2
Daratumumab for hard-to-clear T-cell leukemia traces
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT05298995RecruitingPhase 1
GD2 CAR T-cell treatment for pediatric brain tumors
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
Roma, ItalyAges 6 months–30 years - NCT05285917RecruitingPhase 3
Hydroxyurea safety study for young children with sickle cell
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
LuandaAges 6 months–12 years - NCT05283993Recruiting
Hospital study following people with plasma cell disorders
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
BeijingAges Any age - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Miami, FloridaAges 18 years+ - NCT05268614RecruitingPhase 2
Risk-based reduced chemo and radiation for HPV throat cancer
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
Gainesville, FloridaAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05245656RecruitingPhase 2
Rituximab plus chemo plans for older mantle cell lymphoma
This Phase 2 trial studies whether an “extra chemo” schedule (adding cytarabine) can work better than a standard rituximab-bendamustine plan in older people with mantle cell lymphoma. It compares two treatment sequences to see which one helps patients live longer and respond better with acceptable safety.
Seoul, Gangnam-GuAges 60 years+ - NCT05214742Enrolling by invitation
Using stem cells to study rare growth disorders
This study looks at rare growth conditions (Silver-Russell, Beckwith-Wiedemann, and Temple syndrome) by creating lab cell models from patient information. It aims to help researchers better understand why these disorders happen and how they work.
ParisAges 3 months+ - NCT05242965RecruitingPhase 2
STEMVAC vaccine with pembrolizumab for advanced lung cancer
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
Omaha, NebraskaAges 18 years+ - NCT05246813Recruiting
Study blood cell changes in older adults
This study looks at how blood-forming stem cells change in people with clonal hematopoiesis (CHIP), a common age-related blood condition. It may help researchers understand what these changes mean and who might be at higher risk for future blood problems.
Bonheiden, BelgiëAges 55 years+ - NCT04146298RecruitingPhase 1/Phase 2
KRAS-mutant pancreatic cancer T-cell therapy for some people
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
ShanghaiAges 18–75 - NCT05170412Recruiting
Diet habits study for adults with sickle cell disease
This study asks adults with sickle cell disease about what they eat and their eating routines. The goal is to understand diet patterns in sickle cell and how they may relate to health, which could help future care and guidance.
Bethesda, MarylandAges 18–120 - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.